TCL Archive ASCO Picks Charles Balch To Succeed John Durant as Executive Vice President. January 7, 2000
TCL Archive ODAC Says Clear Clinical Benefit Required When Sponsors Claim Progression Delay July 17, 2009
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004
